Skip to main content
HUADONG MEDICINE CO.,LTD logo

HUADONG MEDICINE CO.,LTD — Investor Relations & Filings

Ticker · 000963 ISIN · CNE0000011S1 LEI · 300300WEZ30P69YUQZ42 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,925 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000963

About HUADONG MEDICINE CO.,LTD

https://www.eastchinapharm.com

HUADONG MEDICINE CO.,LTD. is a comprehensive pharmaceutical enterprise focused on the research, development, production, and distribution of healthcare products. The company operates across the entire pharmaceutical industrial chain, specializing in therapeutic areas such as metabolic diseases, immunology, and oncology. It maintains a significant market presence in the treatment of diabetes and organ transplantation. Beyond traditional pharmaceuticals, the company has established a global leadership position in the medical aesthetics sector through strategic acquisitions and internal development, offering a diverse portfolio of minimally invasive and non-invasive aesthetic products. Its business model integrates industrial manufacturing with commercial distribution, supported by a robust R&D pipeline aimed at innovative drug discovery and high-end medical devices.

Recent filings

Filing Released Lang Actions
关于全资子公司收到药品注册证书的公告
Regulatory Filings Classification · 90% confidence The document is a corporate announcement by 华东医药 regarding its wholly-owned subsidiary receiving drug registration certificates and approvals from the NMPA, including details on product names, indications, registration numbers, and R&D background. It is neither a financial report (Annual, Interim, Audit) nor a specific transaction (M&A, share issue, dividends, board changes, etc.), nor an investor presentation. It is a regulatory announcement of product approval, which best fits the “Regulatory Filings” fallback category (RNS).
2026-05-21 Chinese
浙江天册律师事务所关于华东医药股份有限公司2025年度股东会的法律意见书
AGM Information Classification · 85% confidence The document is a legal opinion letter issued by a law firm regarding the convening procedures, attendee qualifications, and voting process/results for the company’s 2025 annual shareholders’ meeting. It is clearly part of the materials prepared and disclosed for the Annual General Meeting (AGM). This aligns with the “AGM Information” category, which covers presentations and materials shared during the AGM.
2026-05-20 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled “2025年度股东会决议公告” and provides detailed voting results for each proposal at the 2025 Annual General Meeting, including total shares, votes for/against/abstain, and special notes on independent votes. This matches the definition of ‘Declaration of Voting Results & Voting Rights Announcements’ for shareholder votes at a general meeting.
2026-05-20 Chinese
关于参加深圳证券交易所“深研发求精进·积蓄医药成长新动能”2025年度集体业绩说明会的公告
Regulatory Filings Classification · 85% confidence The document is an announcement by East China Pharmaceutical Co., Ltd. about its participation in a Shenzhen Stock Exchange–organized collective performance explanation meeting (“业绩说明会”), including logistics and investor Q&A arrangements. It does not contain any actual financial statements, presentation materials, voting results, or management discussion—it is purely a regulatory notice. This fits the general “Regulatory Filings” category (RNS) for miscellaneous compliance announcements.
2026-05-14 Chinese
关于全资子公司获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 85% confidence The document is a corporate announcement by Huadong Medicine regarding its subsidiary obtaining clinical trial approval from China’s NMPA for a new drug. It does not contain financial statements, dividend info, share transactions, or board changes – it is a regulatory update. It fits the fallback category “Regulatory Filings (RNS)” for general regulatory announcements.
2026-05-13 Chinese
关于参加浙江辖区上市公司2026年投资者网上集体接待日暨2025年度及2026年第一季度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement by Huadong Medicine Co., Ltd. about participating in an online investor collective reception day and an earnings explanation meeting for the 2025 annual report and 2026 Q1 report. It references that the 2025 annual report and 2026 Q1 report have already been published on April 24, 2026. The document invites investors to participate in a webcast event on May 13, 2026, where company executives will discuss the financial results and answer questions. The document itself does not contain any financial statements or substantive financial data, but rather is an announcement about an upcoming investor presentation and Q&A session. It is also relatively short (906 characters). Therefore, this document is best classified as an Investor Presentation (IP) announcement or related event notice. However, since it is primarily an announcement of the event and not the presentation materials themselves, and it is not a full transcript, the best fit is Investor Presentation (IP) as it focuses on financials, strategy, and market position in an investor event context.
2026-05-08 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.